Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs

J Hepatol. 2006 Feb;44(2):317-24. doi: 10.1016/j.jhep.2005.08.006. Epub 2005 Sep 16.

Abstract

Background/aims: We developed a bioartificial liver (BAL) based on a direct hemoperfusion typed nonwoven fabric bioreactor containing porcine hepatocytes. In this study, the efficacy of our BAL was evaluated with a pig fulminant hepatic failure (FHF) model.

Methods: FHF was induced with intravenous administration of D-galactosamine (1.3 g/kg) in each pig. Twelve hours post D-galactosamine injection, fifteen pigs were divided into: a BAL group (n = 5), in which pigs received the BAL treatment with 1.0 to 1.3 x 10(9) hepatocytes for 6 h, a sham BAL group (n = 5), in which pigs received the BAL treatment without hepatocytes, and a FHF group (n = 5), in which pigs only received intensive care. Parameters related to liver function and animal survival up to 168 h were determined.

Results: In the BAL group, blood ammonia and plasma lactate levels were lower, and serum glucose levels and Fischer index were higher than those in the other two groups. Survival time of pigs in the BAL group was significantly prolonged as compared with the sham BAL and the FHF group.

Conclusions: The BAL based on a nonwoven fabric bioreactor containing porcine hepatocytes appears to be effective in the treatment of FHF in pigs.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bioreactors*
  • Disease Models, Animal
  • Equipment Design
  • Galactosamine / toxicity
  • Hemoperfusion / instrumentation*
  • Hepatocytes / cytology*
  • Liver Failure, Acute / chemically induced
  • Liver Failure, Acute / pathology
  • Liver Failure, Acute / therapy*
  • Liver, Artificial*
  • Male
  • Swine
  • Swine, Miniature
  • Textiles*
  • Treatment Outcome

Substances

  • Galactosamine